Skip to Main Content

Amicus Therapeutics (FOLD) is presenting updated results Wednesday from a small clinical trial involving patients with the rare and debilitating Pompe disease. Amicus’ drug continues to improve walking performance and stabilize lung function in patients followed for up to one year.

Data from this same Pompe disease study were last presented by Amicus in October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!